NDC 62175-0470-32: Paroxetine Hydrochloride 12.5 mg Tablet, Film Coated, Extended Release, Bottle of 30
This is a package of 30 tablets of Paroxetine Hydrochloride 12.5 mg Tablet, Film Coated, Extended Release from Lannett Company, LLC, first listed with the FDA Oct 2014 and currently FDA-listed; retail pharmacies pay about $0.4803 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 62175-470-32 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 62175 labeler · 470 product · 32 package
- Package marketed since
- Oct 31, 2014
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Billing quantity
- 30 EA per package
- Barcode (UPC)
- 0362175470324
- Medicaid fills, this package
- 2,324 prescriptions in the last four reported quarters
- FDA record last changed
- Nov 12, 2026
Other active recalls for Paroxetine Hydrochloride (different manufacturers) — 2 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 050137
- GCN: 17078
- HICL (First Databank): 007344
- AHFS class code: 28:16.04.20
- RxCUI (RxNorm): 1738803
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Serotonin Reuptake Inhibitor class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Paroxetine is used to treat depression, panic disorder (sudden, unexpected attacks of extreme fear and worry about these attacks), social anxiety disorder (extreme fear of interacting with others or performing in front of others that interferes with normal life), obsessive-compulsive disorder (bothersome thoughts that won't go away and the need to perform certain actions over and over), generalized anxiety disorder (GAD; excessive worrying that is difficult to control), and posttraumatic stress disorder (disturbing psychological symptoms that develop after a frightening experience). Paroxetine...
Read the full MedlinePlus article ↗- It depends on the form. Tablets and the oral suspension treat depression and several anxiety-related conditions in adults. Extended-release tablets treat depression, panic disorder...
- It’s best not to. Stopping abruptly can cause nausea, dizziness, irritability, trouble sleeping and “electric shock” feelings. Your prescriber should lower your dose gradually.
- The most common are nausea, sleepiness, dry mouth, sweating, constipation or diarrhea, dizziness, tremor and sexual problems. Call your doctor right away for suicidal thoughts, agi...
- Check with me or your prescriber first. It must not be combined with MAOIs, thioridazine or pimozide. Other serotonin-active drugs, blood thinners, aspirin and NSAIDs also need cau...
Patient education
Drug interactions
Supplement & herbal interactions
Paroxetine may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.480 | $14.41 / 30 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.7370 | $22.11 / 30 tablets |
| Medicare drug plans payPart D · Q2 2026 | $1.09 | $32.56 / 30 tablets |
Where does this data come from?
- CMS NADAC weekly file · file of Nov 18, 2026
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 62175-0470-32 You're viewing this Main listing | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE | $0.4803 / ea | $14.41 | 2014-10-31 | — | Active |
| 62175-0470-41 62175-470-41 | 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE | — | — | 2014-10-31 | — | Active |
You're viewing the smallest of 2 pack sizes for this product.
In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 62175-0470-41?
What NDC number is used to bill for this package of Paroxetine Hydrochloride 12.5 mg Tablet, Film Coated, Extended Release?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Paroxetine 12.5 mg 42858-0703-03 | Rhodes | 30 tablets | $0.477 | AB | Discontinued | save 1% |
| Paroxetine Hydrochloride 12.5 mg 60505-1316-03 | Apotex | 30 tablets | $0.480 | AB | Availability likely | — |
| Paroxetine 12.5 mg 62135-0425-30 | Chartwell | 30 tablets | $0.480 | AB | Availability likely | — |
| Paroxetine Hydrochloride 12.5 mgthis 62175-0470-32 | Lannett | 30 tablets | $0.480 | AB | Availability likely | — |
| Paroxetine 12.5 mg 69367-0335-30 | Westminster | 30 tablets | $0.480 | AB | Availability likely | — |
| Paxil Cr 12.5 mg 60505-4377-03 | Apotex | 30 tablets | $9.718 | AB | FDA listed | +1923% |
| Paroxetine 12.5 mg 46708-0766-30 | Alembic | 30 tablets | — | AB | FDA listed | — |
| Paroxetine 12.5 mg 62332-0766-30 | Alembic | 30 tablets | — | AB | FDA listed | — |
| Paroxetine 12.5 mg 63629-9498-01 | Bryant | 30 tablets | — | AB | Discontinued | — |
| Paroxetine 12.5 mg 71209-0094-01 | Cadila | 30 tablets | — | AB | FDA listed | — |
| Paroxetine 12.5 mg 72241-0029-10 | Modavar | 500 tablets | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file · file of Nov 18, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Paroxetine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII B1QE5P712K
Hypromellose 2208 is a plant-derived thickening agent that dissolves in water. It's used as a binder to help hold tablet ingredients together and as a coating on pills to control how quickly the medicine releases in your body.
-
UNII EWQ57Q8I5X
Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII T967IEU43C
A synthetic polymer made from methacrylic acid and ethyl acrylate. It forms a protective coating on tablets and capsules to control how and where the medicine dissolves in the digestive system.
-
UNII 3WJQ0SDW1A
Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
-
UNII 949E52Z6MY
Polyvinyl alcohol is a synthetic polymer made from plant-derived materials. It acts as a binder to hold tablet ingredients together and as a film-former in coatings that control how fast the medicine dissolves.
-
UNII FZ989GH94E
Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
-
UNII 7SEV7J4R1U
A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.
-
UNII 15FIX9V2JP
Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
-
UNII 8Z96QXD6UM
Triethyl citrate is a clear liquid derived from citric acid. It acts as a plasticizer and solvent in tablet coatings and film formulations, helping the coating remain flexible and adhere properly to the medicine.
11 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Lannett Company, LLC labeler code 62175
- Methylphenidate Hydrochloride 36 mg Tablet, Extended Release NDC 62175-312-37
- Methylphenidate Hydrochloride 54 mg Tablet, Extended Release NDC 62175-313-37
- Niacin 500 mg Tablet, Extended Release NDC 62175-320-43
- Niacin 1000 mg Tablet, Extended Release NDC 62175-322-43
- Buprenorphine and Naloxone 2 mg; .5 mg Tablet NDC 62175-452-32
- Buprenorphine and Naloxone 8 mg; 2 mg Tablet NDC 62175-458-32
- Paroxetine Hydrochloride 25 mg Tablet, Film Coated, Extended Release NDC 62175-471-32
- Paroxetine Hydrochloride 37.5 mg Tablet, Film Coated, Extended Release NDC 62175-472-32
- Pantoprazole Sodium 40 mg Tablet, Delayed Release NDC 62175-617-43
- Pantoprazole Sodium 20 mg Tablet, Delayed Release NDC 62175-618-43
- Esomeprazole Magnesium 20 mg Capsule, Delayed Release Pellets NDC 62175-820-32
- Esomeprazole Magnesium 40 mg Capsule, Delayed Release Pellets NDC 62175-840-32
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🚨 Boxed Warning ▾
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . Paroxetine is not approved for use in pediatric patients [see Use in Specific Populations ( 8 .4 ) ] .
WARNING : SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning . Antidepressants increase the risk of suicidal thoughts and behavior in pediatric and young adult patients ( 5.1 ). Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ).
Paroxetine is not approved for use in pediatric patients ( 5.1 , 8.4 ).
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Paroxetine is indicated for the treatment of: Major depressive disorder (MDD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Premenstrual dysphoric disorder (PMDD) in adults Paroxetine is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of ( 1 ): Major depressive disorder (MDD) in adults Panic disorder (PD) in adults Social anxiety disorder (SAD) in adults Premenstrual dysphoric disorder (PMDD) in adults
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION Prior to initiating treatment with Paroxetine, screen patients for a personal or family history of bipolar disorder, mania, or hypomania. ( 2.1 , 5.6 ) Administer Paroxetine once daily in the morning, with or without food. Swallow extended-release tablets whole; do not chew or crush.
( 2.2 ) Recommended starting and maximum daily dosage in table below. ( 2.3 , 2.4 ) Indication Starting Dosage Maximum Dosage MDD 25 mg/day 62.5 mg/day PD 12.5 mg/day 75 mg/day SAD 12.5 mg/day 37.5 mg/day PMDD 12.5 mg/day 25 mg/day For PMDD, dose continuously or intermittently (luteal phase only). ( 2.3 ) Geriatric patients, patients with severe renal impairment or severe hepatic impairment: Starting dosage is 12.5 mg/day and the maximum dosage for MDD or PD is 50 mg/day and for SAD is 37.5 mg/day.
( 2.5 ) When discontinuing Paroxetine, reduce dosage gradually. ( 2.7 )
2.1Screen for Bipolar Disorder Prior to Starting Paroxetine Prior to initiating treatment with Paroxetine, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see Warnings and Precautions ( 5.6 )] .
2.2Important Administration Instructions Administer Paroxetine once daily in the morning, with or without food [see Clinical Pharmacology ( 12.3 )] . Swallow the extended-release tablets whole and do not chew or crush.
2.3Dosage in Patients with Major Depressive Disorder, Panic Disorder, and Social Anxiety Disorder The recommended starting dosage and maximum dosage of Paroxetine in patients with MDD, PD, and SAD are presented in Table 1. In patients with an inadequate response, may increase the Paroxetine dosage by 12.5 mg/day at weekly intervals (e.g., if the starting dosage is 12.5 mg/day may increase the dosage the next week to 25 mg/day), depending on tolerability, up to the maximum recommended dosage. Table 1: Recommended Daily Dosage of Paroxetine in Patients with MDD, PD, and SAD Indication Starting Dosage Maximum Dosage MDD 25 mg 62.5 mg PD 12.5 mg 75 mg SAD 12.5 mg 37.5 mg
2.4Dosage in Patients with Premenstrual Dysphoric Disorder The recommended starting dosage of Paroxetine in women with PMDD is 12.5 mg/day. Administer Paroxetine either: Continuously (every day throughout the menstrual cycle) or Intermittently with each new cycle (only during the luteal phase of the menstrual cycle, i.e., starting the daily dosage 14 days prior to the anticipated onset of menstruation and continuing through the onset of menses). In patients with an inadequate response, may increase the Paroxetine dosage by 12.5 mg/day at weekly intervals (e.g., after 1 week may increase the dosage from 12.5 mg/day to 25 mg/day) to the maximum recommended dosage of 25 mg/day, depending on tolerability.
2.5Recommended Dosage in Geriatric Patients, Patients with Severe Renal Impairment and Patients with Severe Hepatic Impairment For the treatment of MDD, PD, SAD, or PMDD in geriatric patients (those 65 years of age or older), patients with severe renal impairment, and patients with severe hepatic impairment [see Use in Specific Populations ( 8.5 , 8.6 , 8.7 )] : The recommended starting dosage of Paroxetine is 12.5 mg/day. If these patients have an inadequate response, may increase the Paroxetine dosage by 12.5 mg/day at weekly intervals (e.g., after 1 week, may increase the dosage from 12.5 mg/day to 25 mg/day) up to the maximum recommended dosage.
The maximum recommended dosage is 50 mg/day for MDD or PD; 37.5 mg/day for SAD; and 25 mg/day for PMDD. In these patients with PMDD, may administer Paroxetine intermittently [see Dosage and Administration ( 2.3 )] .
2.6Switching Patients to or from a Monoamine Oxidase Inhibitor Antidepressant At least 14 days must elapse between discontinuation of an monoamine oxidase inhibitor (MAOI) antidepressant and initiation of Paroxetine. In addition, at least 14 days must elapse after stopping Paroxetine before starting an MAOI antidepressant [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )]… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Paroxetine Extended-Release Tablets, USP are supplied as film-coated, extended-release, round convex tablets, as follows: 12.5 mg white tablets (debossed with “KU” on one side and “470” on the other) 25 mg pink tablets (debossed with “KU” on one side and “471” on the other) 37.5 mg blue tablets (debossed with “KU” on one side and “472” on the other) Extended-release tablets: 12.5 mg, 25 mg, and 37.5 mg. ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS Paroxetine is contraindicated in patients: Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions ( 5.2 ) and Drug Interactions ( 7 )] . Who receive drugs that can prolong QTc interval and are also CYP2D6 substrates [see Drug Interactions ( 7 ) and Warnings and Precautions ( 5.3 )]. With known hypersensitivity to paroxetine or to any of the inactive ingredients in Paroxetine.
Hypersensitivity reactions have included anaphylaxis, angioedema, and Stevens-Johnson syndrome [see Adverse Reactions ( 6.1 , 6.2 )] . Paroxetine is contraindicated in patients: Taking, or within 14 days of stopping monoamine oxidase inhibitors (MAOIs). ( 4 , 5.2 , 7 ) Who receive drugs that can prolong QTc interval and are also CYP2D6 substrates.
( 4 , 5.3 , 7 ) Known hypersensitivity to paroxetine or to any of the inactive ingredients in Paroxetine. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Serotonin Syndrome: Monitor all patients taking Paroxetine for the emergence of serotonin syndrome. If occurs, discontinue Paroxetine and serotonergic agents and initiate supportive measures. ( 5.2 ) Embryofetal Toxicity: For women who intend to become pregnant or who are in their first trimester of pregnancy, Paroxetine, should be initiated only after consideration of the other available treatment options.
( 5.4 , 8.1 ) Increased Risk of Bleeding: For patients taking warfarin, carefully monitor the international normalized ratio when initiating, titrating, or discontinuing Paroxetine. ( 5.5 ) Seizures: Use with caution in patients with seizure disorders and Paroxetine should be discontinued in patients who develop a seizure. ( 5.8 ) Angle-Closure Glaucoma: Avoid use of Paroxetine in patients with untreated anatomically narrow angles.
( 5.9 ) Hyponatremia: In patients with symptomatic hyponatremia, discontinue Paroxetine and institute appropriate medical intervention. ( 5.10 ) Sexual Dysfunction: Inquire about sexual function prior to initiation of Paroxetine and to inquire specifically about changes in sexual function during Paroxetine treatment. ( 5.11 )
5.1Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There were differences in absolute risk of suicidal thoughts and behaviors across the different uses, with the highest incidence in patients with MDD.
The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 2. Table 2: Risk Differences of the Number of Patients with Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric 1 and Adult Patients Age Range Drug-Placebo Difference in Number of Patients of Suicidal Thoughts and Behaviors per 1,000 Patients Treated Increases Compared to Placebo <18 years old 14 additional patients 18-24 years old 5 additional patients Decreases Compared to Placebo 25-64 years old 1 fewer patient ≥65 years old 6 fewer patients 1 Paroxetine is not approved for use in pediatric patients.
It is unknown whether the risk of suicidal thoughts and behaviors in pediatric patients and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors. Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes.
Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing Paroxetine, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.
5.2Serotonin Syndrome Selective serotonin reuptake inhibitors (SSRIs, including Paroxetine, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications ( 4 ), Drug Interactions ( 7.1 )] .
Serotonin syndrome can also occur when Paroxetine is used alone. Serotonin… [Excerpted — this section continues on DailyMed.]
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following adverse reactions are included in more detail in other sections of the prescribing information: Suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] Serotonin syndrome [see Warnings and Precautions ( 5.2 )] Increased risk of bleeding [see Warnings and Precautions ( 5.5 )] Activation of mania/hypomania [see Warnings and Precautions ( 5.6 )] Discontinuation syndrome [see Warnings and Precautions ( 5.7 )] Seizures [see Warnings and Precautions ( 5.8 )] Angle-closure glaucoma [see Warnings and Precautions ( 5.9 )] Hyponatremia [see Warnings and Precautions ( 5.10 )] Sexual dysfunction [see Warnings and Precautions ( 5.
11 )] Risk of fracture [see Warnings and Precautions ( 5.12 )] Most common adverse reactions (≥5% and at least twice placebo) in placebo-controlled MDD, PD, SAD, and PMDD clinical trials: abnormal ejaculation, abnormal vision, asthenia, constipation, decreased appetite, diarrhea, dizziness, dry mouth, female genital disorder, impotence, insomnia, libido decreased, nausea, somnolence, sweating, tremor. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc. at 1-844-834-0530 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Safety data for Paroxetine are from 11 short-term, placebo-controlled clinical trials including 3 studies in patients with major depressive disorder (MDD) (Studies 1, 2, and 3), 3 studies in patients with panic disorder (PD) (Studies 4, 5, and 6), 1 study in patients with social anxiety disorder (SAD) (Study 7), and 4 studies in female patients with premenstrual dysphoric disorder (PMDD) (Studies 8, 9, 10, and 11) [see Clinical Studies ( 14 )] .
These 11 trials included 1,627 patients treated with Paroxetine. Studies 1 and 2 were 12-week studies that enrolled patients 18 to 65 years old with MDD.Patients in the Paroxetine group received Paroxetine at a dosage that ranged from 25 mg to 62.5 mg once daily. Study 3 was a 12-week study in patients 60 to 88 years old with MDD.
Patients in the Paroxetine group received Paroxetine at a dosage that ranged from 12.5 mg to 50 mg once daily. Studies 4, 5, and 6 were 10-week studies in patients 19 to 72 years old with PD. Patients in the Paroxetine group received Paroxetine at a dosage that ranged from 12.5 mg to 75 mg once daily.
Study 7 was a 12-week study that enrolled adult patients. Patients in the Paroxetine group received Paroxetine with SAD at a dosage that ranged from 12.5 mg to 37.5 mg once daily. Studies 8, 9, and 10 were 12-week, placebo-controlled trials in female patients 18 to 46 years old with PMDD.
Patients in the Paroxetine group received Paroxetine at a dosage of 12.5 mg or 25 mg once daily. Study 11 was a 12-week placebo-controlled trial in patients 18 to 46 years old with PMDD. Patients in the Paroxetine group received Paroxetine two weeks prior to the onset of each menses (luteal phase dosing) at a dosage of 12.5 mg or 25 mg once daily.
Adverse Reactions that Led to Discontinuation in Patients with MDD, PD, SAD, and PMDD In pooled studies in patients with MDD, PD and SAD, the most common adverse reactions that led to study withdrawal in the Paroxetine-treated patients were nausea (up to 4% of patients), asthenia, headache, depression, insomnia, and abnormal liver function tests (each occurred in up to 2% of patients), and dizziness, somnolence, and diarrhea (each occurred up to 1% of patients). In pooled studies for PMDD, the most common adverse reactions that led to study withdrawal in the Paroxetine-treated patients were nausea (occurred in up to 6% of patients), asthenia (occurred in up to 5% of patients), somnolence (occurred in up to 4% of patients), insomnia (occurred i… [Excerpted — this section continues on DailyMed.]
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS Drugs Highly Bound to Plasma Protein: Monitor for adverse reactions and reduce dosage of Paroxetine or other protein-bound drugs (e.g., warfarin) as warranted. ( 7 ) CYP2D6 Substrates: Reduce dosage of the CYP2D6 substrate if needed. ( 7 ) Concomitant use with Tamoxifen: Consider use of an alternative antidepressant with little or no CYP2D6 inhibition. ( 5.11 , 7 )
7.1Clinically Significant Drug Interactions Table 6 includes clinically significant drug interactions with Paroxetine. Table 6: Clinically Significant Drug Interactions with Paroxetine Monoamine Oxidase Inhibitors (MAOIs) Mechanism and Clinical Effect(s) The concomitant use of SSRIs, including Paroxetine and MAOIs increases the risk of serotonin syndrome. Prevention or Management Paroxetine is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.2 )] .
CYP2D6 Substrates that Prolong the QTc Interval Mechanism and Clinical Effect(s) Paroxetine is a CYP2D6 inhibitor. Concomitant use of Paroxetine with CYP2D6 substrates that prolong the QTc interval can increase the concentration of those CYP2D6 substrates and may result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation [see Warnings and Precautions ( 5.3 )]. Prevention or Management Paroxetine use is contraindicated in patients who receive drugs that can prolong QTc interval and are CYP2D6 substrates .
Other Serotonergic Drugs Mechanism and Clinical Effect(s) The concomitant use of serotonergic drugs with Paroxetine increases the risk of serotonin syndrome. Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome with concomitant use of Paroxetine and other serotonergic drugs, If serotonin syndrome occurs, immediately discontinue treatment with Paroxetine and/or concomitant serotonergic drugs [see Warnings and Precautions ( 5.2 )] . Drugs that Interfere with Hemostasis (antiplatelet drugs and anticoagulants) Mechanism and Clinical Effect(s) The concomitant use of an antiplatelet drug or anticoagulant with Paroxetine may potentiate the risk of bleeding.
Prevention or Management Inform patients of the increased risk of bleeding associated with the concomitant use of Paroxetine and antiplatelet drugs and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio when initiating, titrating, or discontinuing Paroxetine [see Warnings and Precautions ( 5.5 )] . Drugs Highly Bound to Plasma Protein Mechanism and Clinical Effect(s) Paroxetine is highly bound to plasma protein.
The concomitant use of Paroxetine with another drug that is highly bound to plasma protein may increase free concentrations of paroxetine or other tightly-bound drugs in plasma . Prevention or Management Monitor for adverse reactions and reduce dosage of Paroxetine or other protein-bound drugs as warranted. CYP2D6 Substrates Mechanism and Clinical Effect(s) Paroxetine is a strong CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )].
The concomitant use of Paroxetine with a CYP2D6 substrate may increase the exposure of the CYP2D6 substrate and increase the risk of CYP2D6 substrate-associated adverse reactions. Prevention or Management With concomitant use with Paroxetine, decrease the dosage of a CYP2D6 substrate if needed. Tamoxifen Mechanism and Clinical Effect(s) Concomitant use of tamoxifen with Paroxetine may lead to reduced plasma concentrations of the active metabolite of tamoxifen (i.e., endoxifen) and reduced efficacy of tamoxifen.
Prevention or Management Consider use of an alternative antidepressant with little or no CYP2D6 inhibition when tamoxifen is used for the treatment or prevention of breast cancer [see Warnings and Precautions ( 5.11 )]. Fosamprenavir/Ritonavir Mechanism and Clinical Effect(s) Concomitant use of fosamprenavir/ritonavir with paroxetine significantly decrea… [Excerpted — this section continues on DailyMed.]
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS Pregnancy : Advise women of the risks associated with first trimester use of Paroxetine, risks associated with third trimester use of Paroxetine including an increased risk for neonatal complications including persistent pulmonary hypertension of the newborn. Also, advise women of the risks associated with untreated depression in pregnancy in those being treated for MDD ( 8.1 ). SSRI use, particularly later in pregnancy, may increase neonatal risks of persistent pulmonary hypertension and symptoms of poor adaptation (respiratory distress, temperature instability, feeding difficulty, hypotonia, irritability).
Paroxetine should be initiated only after consideration of the other available treatment options ( 5.4 , 8.1 ). Lactation: Infants exposed to Paroxetine through breastfeeding should be monitored for agitation, irritability, poor feeding and poor weight gain ( 8.2 ). Males of Reproductive Potential: Paroxetine may affect sperm quality which may impair fertility; it is not known if this effect is reversible ( 8.3 ) .
8.1Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/antidepressants/. Risk Summary For women who intend to become pregnant or who are in their first trimester of pregnancy, Paroxetine should be initiated only after consideration of the other available treatment options.
There are risks of persistent pulmonary hypertension of the newborn (PPHN) (see Data ) and/or poor neonatal adaptation with exposure to SSRIs, including Paroxetine, during pregnancy. Based on data from published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions ( 5.5 ) and Clinical Considerations ]. Paroxetine is associated with a less than 2-fold increase in cardiovascular malformations when administered to a pregnant woman during the first trimester.
While individual epidemiological studies on the association between paroxetine use and cardiovascular malformations have reported inconsistent findings, some meta-analyses of epidemiological studies have identified an increased risk of cardiovascular malformations (see Data ). Also, consider the risks of untreated depression when discontinuing or changing treatment with antidepressants during pregnancy and the postpartum period (see Clinical Considerations ). No evidence of treatment related malformations was observed in animal reproduction studies, when paroxetine was administered during the period of organogenesis at doses up to 50 mg/kg/day in rats and 6 mg/kg/day in rabbits.
These doses are approximately in rats are approximately 6 times the maximum recommended human dose (MRHD – 75 mg) of Paroxetine and in rabbits less than 2 times the MRHD on an mg/m 2 basis. When paroxetine was administered to female rats during the last trimester of gestation and continued through lactation, there was an increase in the number of pup deaths during the first four days of lactation. This effect occurred at a dose of 1 mg/kg/day which is less than the MRHD on an mg/m 2 basis (see Data ).
The estimated background risks of major birth defects and miscarriage for pregnant adults with MDD, PD, SAD, or PMDD are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Disease-associated Maternal and/or Embryo/fetal Risk: Women who discontinue antidep… [Excerpted — this section continues on DailyMed.]
🤰 Pregnancy ▾
8.1Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/antidepressants/. Risk Summary For women who intend to become pregnant or who are in their first trimester of pregnancy, Paroxetine should be initiated only after consideration of the other available treatment options.
There are risks of persistent pulmonary hypertension of the newborn (PPHN) (see Data ) and/or poor neonatal adaptation with exposure to SSRIs, including Paroxetine, during pregnancy. Based on data from published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions ( 5.5 ) and Clinical Considerations ]. Paroxetine is associated with a less than 2-fold increase in cardiovascular malformations when administered to a pregnant woman during the first trimester.
While individual epidemiological studies on the association between paroxetine use and cardiovascular malformations have reported inconsistent findings, some meta-analyses of epidemiological studies have identified an increased risk of cardiovascular malformations (see Data ). Also, consider the risks of untreated depression when discontinuing or changing treatment with antidepressants during pregnancy and the postpartum period (see Clinical Considerations ). No evidence of treatment related malformations was observed in animal reproduction studies, when paroxetine was administered during the period of organogenesis at doses up to 50 mg/kg/day in rats and 6 mg/kg/day in rabbits.
These doses are approximately in rats are approximately 6 times the maximum recommended human dose (MRHD – 75 mg) of Paroxetine and in rabbits less than 2 times the MRHD on an mg/m 2 basis. When paroxetine was administered to female rats during the last trimester of gestation and continued through lactation, there was an increase in the number of pup deaths during the first four days of lactation. This effect occurred at a dose of 1 mg/kg/day which is less than the MRHD on an mg/m 2 basis (see Data ).
The estimated background risks of major birth defects and miscarriage for pregnant adults with MDD, PD, SAD, or PMDD are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Disease-associated Maternal and/or Embryo/fetal Risk: Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continue antidepressants. This finding is from a prospective longitudinal study of 201 pregnant women with a history of MDD who were euthymic and taking antidepressants at the beginning of pregnancy. Maternal Adverse Reactions: Use of Paroxetine in the month before delivery may be associated with an increased risk of postpartum hemorrhage [see Warnings and Precautions ( 5.5 )] .
Fetal/Neonatal Adverse Reactions: Neonates of mothers exposed to Paroxetine and other SSRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremors, jitteriness, irritability, and constant crying.
These findings are consistent with either a dir… [Excerpted — this section continues on DailyMed.]
🧒 Pediatric Use ▾
8.4Pediatric Use The safety and effectiveness of Paroxetine in pediatric patients have not been established. Safety and effectiveness of paroxetine for the treatment of MDD in pediatric patients was not demonstrated in three placebo-controlled trials in 752 pediatric patients with MDD treated with immediate-release paroxetine tablets. Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients [see Warnings and Precautions ( 5.1 )].
Decreased appetite and weight loss have been observed in association with the use of SSRIs in pediatric patients. In placebo-controlled clinical trials conducted with pediatric patients, the following adverse reactions were reported in at least 2% of pediatric patients treated with immediate-release paroxetine tablets and at a rate at least twice that for pediatric patients treated with placebo: emotional lability (including self-harm, suicidal thoughts, attempted suicide, crying, and mood fluctuations), hostility, decreased appetite, tremor, sweating, hyperkinesia, and agitation.
Adverse reactions upon discontinuation of immediate-release paroxetine tablet treatment (occurred in at least 2% of paroxetine-treated patients and at a rate at least twice that of placebo-treated patients) in the pediatric clinical trials that included a taper phase regimen, were emotional lability (including suicidal ideation, suicide attempt, mood changes, and tearfulness), nervousness, dizziness, nausea, and abdominal pain .
🧓 Geriatric Use ▾
8.5Geriatric Use SSRIs and SNRIs, including Paroxetine, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse reaction [see Warnings and Precautions ( 5.9 ) ] . In premarketing clinical trials with immediate release paroxetine tablets, 17% of paroxetine-treated patients (approximately 700) were 65 years or older. Clinical studies of Paroxetine did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
The minimum plasma concentration (C min ) of paroxetine was higher in immediate release paroxetine-treated patients 65 years of age and older compared to younger adult patients [see Clinical Pharmacology ( 12.3 )]; therefore, the recommended starting Paroxetine dosage is lower in patients 65 years of age and older for the treatment of MDD and the maximum recommended is lower in patients 65 years of age and older with MDD and PD [see Dosage and Administration ( 2 )].
🆘 Overdosage ▾
10 OVERDOSAGE The following overdose complications have been reported with paroxetine overdose: Seizures, which may be delayed, and altered mental status including coma. Cardiovascular toxicity, which may be delayed, including QRS and QTc interval prolongation. Hypertension most commonly seen, but rarely can see hypotension alone or with concomitant products including alcohol.
Serotonin syndrome (patients with a multiple drug overdose with other proserotonergic drugs may have a higher risk). If an overdose occurs, consider contacting a Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The mechanism of action of Paroxetine in the treatment of major depressive disorder (MDD), panic disorder (PD), social anxiety disorder (SAD), and premenstrual dysphoric disorder (PMDD) is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-HT).
12.2Pharmacodynamics Studies at clinically relevant paroxetine dosage in humans have demonstrated that paroxetine blocks the uptake of serotonin into human platelets. In vitro studies in animals also suggest that paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake (SSRI) and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Cardiac Electrophysiology At the maximum recommended paroxetine dose, a mean increase in the QTc interval >20 milliseconds is unlikely.
12.3Pharmacokinetics During repeated administration of Paroxetine (25 mg once daily), steady state was reached within 2 weeks (i.e., comparable to immediate-release dosage forms). In a repeat-dose study in which healthy male and female subjects (n = 23) received Paroxetine (25 mg daily), mean steady state C max , C min , and AUC 0-24 values were 30 ng/mL, 20 ng/mL, and 550 ng•hr./mL, respectively. Based on studies using immediate-release paroxetine, steady-state paroxetine exposure based on AUC 0-24h was several-fold greater than that of the single-dose data.
In steady-state dose proportionality studies with elderly and nonelderly adult patients, at doses of the immediate-release paroxetine of 20 mg to 40 mg daily for the elderly and 20 mg to 50 mg daily for the nonelderly, some nonlinearity was observed in both populations, reflecting a saturable metabolic pathway (Figure 3). Absorption Following administration of single oral doses of Paroxetine (i.e., 12.5 mg, 25 mg, 37.5 mg, or 50 mg) in healthy subjects, paroxetine C max and AUC 0-inf increased disproportionately with dose (as seen also with immediate-release dosage forms).
Mean C max and AUC 0-inf values at these doses were 2, 5.5, 9, and 12.5 ng/mL, and 121, 261, 338, and 540 ng•hr. /mL, respectively. T max was observed typically between 6- and-10 hours post-dose, reflecting a reduction in absorption rate compared with immediate-release dosage forms. Food Effect: Food did not appreciably affect the bioavailability of Paroxetine 25 mg Distribution Paroxetine distributes throughout the body, including the central nervous system (CNS), with only 1% remaining in the plasma.
Approximately 95% and 93% of paroxetine is bound to plasma protein at 100 ng/mL and 400 ng/mL, respectively. Under clinical conditions, paroxetine concentrations would normally be less than 400 ng/mL. Paroxetine does not alter the in vitro protein binding of phenytoin or warfarin.
Elimination The elimination half-life was approximately 15 to 20 hours after a single dose of Paroxetine. Metabolism: Paroxetine is extensively metabolized after oral Paroxetine administration. The principal metabolites are polar and conjugated products of oxidation and methylation, which are readily cleared.
Conjugates with glucuronic acid and sulfate predominate, and major metabolites have been isolated and identified. Data indicate that the metabolites have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake. The metabolism of paroxetine is accomplished in part by CYP2D6.
Saturation of this enzyme at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment. The role of this enzyme in paroxetine metabolism also suggests potential drug-drug interactions [see Drug Interactions ( 7.1 )] . Excretion: Approximately 64% of 30-mg dose of paroxetine oral solution was excreted in the urine with 2% as the parent compound and 62% as metabolites over a 10-day post-dosing period.
About 36% was excreted in the… [Excerpted — this section continues on DailyMed.]
🧬 Mechanism of Action ▾
12.1Mechanism of Action The mechanism of action of Paroxetine in the treatment of major depressive disorder (MDD), panic disorder (PD), social anxiety disorder (SAD), and premenstrual dysphoric disorder (PMDD) is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-HT).
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING Paroxetine Extended-Release Tablets, USP are supplied as film-coated, extended-release, round convex tablets, as follows: 12.5 mg white tablets (debossed with “KU” on one side and “470” on the other) NDC 62175-470-32 Bottles of 30 NDC 62175-470-41 Bottles of 500 25 mg pink tablets (debossed with “KU” on one side and “471” on the other) NDC 62175-471-32 Bottles of 30 NDC 62175-471-41 Bottles of 500 37.5 mg blue tablets (debossed with “KU” on one side and “472” on the other) NDC 62175-472-32 Bottles of 30 NDC 62175-472-41 Bottles of 500 Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].
📋 Description ▾
11 DESCRIPTION Paroxetine Extended-Release Tablets, USP contain paroxetine hydrochloride, an SSRI. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)- trans -4 R- (4'-fluorophenyl)-3 S -[(3',4'-methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C 19 H 20 FNO 3 •HCl•1/2H 2 O. The molecular weight is 374.8 g/mol (329.4 g/mol as free base).
The structural formula of paroxetine hydrochloride is: Paroxetine hydrochloride is an odorless, off-white powder, having a melting point range of 120°C to 138°C and a solubility of 5.4 mg/mL in water. Paroxetine Extended-Release Tablets, USP are for oral administration. Each enteric, film-coated, extended-release tablet contains paroxetine hydrochloride equivalent to paroxetine as follows: 12.5 mg–white, 25 mg–pink and 37.5 mg–blue.
Inactive ingredients consist of hypromellose, lactose monohydrate, magnesium stearate, methacrylic acid and ethyl acrylate copolymer dispersion, polyethylene glycols, polyvinyl alcohol, povidone, silicon dioxide, talc, titanium dioxide, triethyl citrate. In addition, the 25 mg and 37.5 mg colorant contains FD&C Blue No. 2 aluminum lake.
In addition, the 25 mg colorant also contains carmine. Paroxetine meets USP Dissolution Test 3. Formula
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ). Suicidal Thoughts and Behaviors Advise patients and caregivers to look for the emergence of suicidal thoughts and behaviors, especially early during Paroxetine treatment and when the dosage is adjusted up or down, and instruct them to report such symptoms to the healthcare provider [see Warnings and Precautions ( 5.1 )] . Serotonin Syndrome Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of Paroxetine with other serotonergic drugs.
Instruct patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome [see Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )] . Potential for Drug Interactions with Concomitant Drugs Advise patients to inform their healthcare provider if they are taking, or plan to take, any prescription or nonprescription drugs, since there is a potential for drug-drug interactions [see Warning and Precautions ( 5.3 ), Drug Interactions ( 7 )]. Increased Risk of Bleeding Inform patients that the concomitant use of Paroxetine with aspirin, NSAIDs, other antiplatelet drugs, warfarin, or other anticoagulants has been associated with an increased risk of bleeding.
Advise patients to inform their healthcare providers if they are taking or planning to take any prescription or non-prescription drug that increases the risk of bleeding [see Warnings and Precautions ( 5.5 )] . Activation of Mania/Hypomania Advise patients and their caregivers to observe for signs of activation of mania/hypomania and instruct them to report such symptoms to their healthcare provider [see Warnings and Precautions ( 5.6 )] . Discontinuation Syndrome Advise patients not to abruptly discontinue Paroxetine and to discuss any tapering regimen with their healthcare provider.
Inform patients that adverse reactions can occur when Paroxetine is discontinued [see Warnings and Precautions ( 5.7 )] . Sexual Dysfunction Advise female and male patients that use of Paroxetine may cause symptoms of sexual dysfunction. Inform patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider [see Warnings and Precautions ( 5.11 )] .
Embryo-Fetal Toxicity Advise women to notify their health care provider if they become pregnant or intend to become pregnant during treatment with Paroxetine. Advise women of the risks of Paroxetine associated with [see Warnings and Precautions ( 5.4 , 5.5 ), Use in Specific Populations ( 8.1 )] : First trimester use. Third trimester use including an increased risk for neonatal complications requiring prolonged hospitalization, respiratory support, tube feeding, and/or persistent pulmonary hypertension of the newborn.
Advise women of the risks associated with untreated depression in pregnancy in those being treated for MDD. Advise women of the availability of a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Paroxetine during pregnancy. Lactation Advise breastfeeding women using Paroxetine to monitor infants for agitation, irritability, poor feeding and poor weight gain and to seek medical care if they notice these signs [see Use in Specific Populations ( 8.2 )] .
Males of Reproductive Potential Advise men that Paroxetine may affect sperm quality, which may impair fertility; it is unknown if this effect is reversible [see Use in Specific Populations ( 8.3 )] . Hypersensitivity Reactions Advise patients to notify their healthcare provider if they develop a hypersensitivity reaction such as rash, hives, swelling, or difficulty breathing [see Adverse Reactions ( 6.1 , 6.2 )] . Important Administration Instructions Instruct patients to swallow Paroxetine whole and to not chew or crush the extended-release tablets [see Dosage and Administration ( 2.1 )] .
Distributed by: Lannett Company, Inc. Phil… [Excerpted — this section continues on DailyMed.]
💬 Medication Guide ▾
MEDICATION GUIDE Paroxetine (pa rox` e tine) Extended-Release Tablets, USP, for oral use What is the most important information I should know about Paroxetine? Paroxetine can cause serious side effects, including: Increased risk of suicidal thoughts and actions. Paroxetine and other antidepressant medicines may increase the risk of suicidal thoughts and actions in people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed.
Paroxetine is not for use in children. Depression or other mental illnesses are the most important causes of suicidal thoughts or actions. How can I watch for and try to prevent suicidal thoughts and actions?
Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts or feelings or if you develop suicidal thoughts or actions. This is very important when an antidepressant medicine is started or when the dose is changed. Tell your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts or feelings or if you develop suicidal thoughts or actions.
Keep all follow-up visits with your healthcare provider as scheduled. Tell your healthcare provider between visits as needed, especially if you have concerns about symptoms. Tell your healthcare provider or get emergency medical help right away if you develop any of the following symptoms, especially if they are new, worse, or worry you: suicide attempts acting aggressive or violent new or worse depression feeling agitated, restless, angry, or irritable an increase in activity and talking more than what is normal for you acting on dangerous impulses thoughts about suicide or dying new or worse anxiety or panic attacks trouble sleeping other unusual changes in behavior or mood See “What are the possible side effects of Paroxetine?” for more information about side effects.
What is Paroxetine? Paroxetine is a prescription medicine used in adults to treat: A certain type of depression called major depressive disorder (MDD) Panic disorder Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD) It is not known if Paroxetine is safe and effective in children. Who should not take Paroxetine?
Do not take Paroxetine if you: are taking, or have stopped taking within the last 14 days, a medicine called a monoamine oxidase inhibitor (MAOI), including the antibiotic linezolid or intravenous methylene blue are taking certain medicines that can cause a heart rhythm problem called QT prolongation are allergic to paroxetine or any of the ingredients in Paroxetine. See the end of this Medication Guide for a complete list of ingredients in Paroxetine. Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI or one of these medicines.
Do not start taking an MAOI for at least 14 days after you stop treatment with Paroxetine. Before taking Paroxetine, tell your healthcare provider about all your medical conditions, including if you: have heart problems have or had bleeding problems have, or have a family history of, bipolar disorder, mania or hypomania have or had seizures or convulsions have high pressure in the eye (glaucoma) have low sodium levels in your blood have bone problems have kidney or liver problems are pregnant or plan to become pregnant.
Paroxetine can harm your unborn baby. Taking Paroxetine during your first trimester of pregnancy may cause your baby to be at an increased risk of having a heart problem (cardiac malformations) at birth. Taking Paroxetine during your third trimester of pregnancy may cause your baby to have breathing, temperature, and feeding problems, low muscle tone, and irritability after birth and may cause your baby to be at an increased risk of a serious lung problem at birth.
Talk to your healthcare provider about the risks to your unborn baby if you take Paroxetine during pregnancy. You may be at increased risk for bleeding after childbirth if you take Paroxetine in the month before delivery. Te… [Excerpted — this section continues on DailyMed.]
🍼 Nursing Mothers ▾
8.3Females and Males of Reproductive Potential Infertility Males: Based on findings from clinical studies, paroxetine may affect sperm quality which may impair fertility; it is not known if this effect is reversible [see Nonclinical Toxicology ( 13.1 )] .
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics During repeated administration of Paroxetine (25 mg once daily), steady state was reached within 2 weeks (i.e., comparable to immediate-release dosage forms). In a repeat-dose study in which healthy male and female subjects (n = 23) received Paroxetine (25 mg daily), mean steady state C max , C min , and AUC 0-24 values were 30 ng/mL, 20 ng/mL, and 550 ng•hr./mL, respectively. Based on studies using immediate-release paroxetine, steady-state paroxetine exposure based on AUC 0-24h was several-fold greater than that of the single-dose data.
In steady-state dose proportionality studies with elderly and nonelderly adult patients, at doses of the immediate-release paroxetine of 20 mg to 40 mg daily for the elderly and 20 mg to 50 mg daily for the nonelderly, some nonlinearity was observed in both populations, reflecting a saturable metabolic pathway (Figure 3). Absorption Following administration of single oral doses of Paroxetine (i.e., 12.5 mg, 25 mg, 37.5 mg, or 50 mg) in healthy subjects, paroxetine C max and AUC 0-inf increased disproportionately with dose (as seen also with immediate-release dosage forms).
Mean C max and AUC 0-inf values at these doses were 2, 5.5, 9, and 12.5 ng/mL, and 121, 261, 338, and 540 ng•hr. /mL, respectively. T max was observed typically between 6- and-10 hours post-dose, reflecting a reduction in absorption rate compared with immediate-release dosage forms. Food Effect: Food did not appreciably affect the bioavailability of Paroxetine 25 mg Distribution Paroxetine distributes throughout the body, including the central nervous system (CNS), with only 1% remaining in the plasma.
Approximately 95% and 93% of paroxetine is bound to plasma protein at 100 ng/mL and 400 ng/mL, respectively. Under clinical conditions, paroxetine concentrations would normally be less than 400 ng/mL. Paroxetine does not alter the in vitro protein binding of phenytoin or warfarin.
Elimination The elimination half-life was approximately 15 to 20 hours after a single dose of Paroxetine. Metabolism: Paroxetine is extensively metabolized after oral Paroxetine administration. The principal metabolites are polar and conjugated products of oxidation and methylation, which are readily cleared.
Conjugates with glucuronic acid and sulfate predominate, and major metabolites have been isolated and identified. Data indicate that the metabolites have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake. The metabolism of paroxetine is accomplished in part by CYP2D6.
Saturation of this enzyme at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment. The role of this enzyme in paroxetine metabolism also suggests potential drug-drug interactions [see Drug Interactions ( 7.1 )] . Excretion: Approximately 64% of 30-mg dose of paroxetine oral solution was excreted in the urine with 2% as the parent compound and 62% as metabolites over a 10-day post-dosing period.
About 36% was excreted in the feces (probably via the bile), mostly as metabolites and less than 1% as the parent compound over the 10-day post-dosing period. Drug Interaction Studies There are clinically significant, known drug interactions between paroxetine and other drugs [see Drug Interactions ( 7 )] . See Figure 1 for the impact of paroxetine on the pharmacokinetics of concomitantly administered drugs and Figure 2 for the impact of other drugs on paroxetine pharmacokinetics.
Figure 1. Impact of Paroxetine on the Pharmacokinetics of Concomitantly Administered Drugs (log scale) Pimozide is a moderately sensitive CYP3A4 substrate and is a CYP2D6 substrate; desipramine is a sensitive 2D6 substrate; propranolol is a moderately sensitive 2D6 substrate, digoxin is P-gp substrate, and phenytoin is a strong 3A4 inhibitor. Figure 2.
Impact of Concomitantly Administered Drugs on the Pharmacokinetics of Paroxetine Cimetidine is a OCT2, MATE1, and MATE2-K inhib… [Excerpted — this section continues on DailyMed.]
🧬 Pharmacodynamics ▾
12.2Pharmacodynamics Studies at clinically relevant paroxetine dosage in humans have demonstrated that paroxetine blocks the uptake of serotonin into human platelets. In vitro studies in animals also suggest that paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake (SSRI) and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Cardiac Electrophysiology At the maximum recommended paroxetine dose, a mean increase in the QTc interval >20 milliseconds is unlikely.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES
14.1Clinical Studies in Major Depressive Disorder The efficacy of Paroxetine for the treatment for major depressive disorder (MDD) was established in: Two 12-week, multicenter, randomized, double-blind, placebo-controlled, flexible-dose studies with Paroxetine (Studies 1 and 2) in adult patients who met Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for MDD. Studies 1 and 2 included patients 18 to 65 years old who received a Paroxetine dosage of 25 mg to 62.5 mg (N=212) or placebo (N=211) once daily compared to immediate-release paroxetine tablets 20 mg/day to 50 mg/day (N=217).
One 12-week, multicenter, randomized, double-blind, placebo-controlled, flexible dose study with Paroxetine (Study 3) in elderly patients, with an age range from 60 to 88 years old, with MDD. Patients received a Paroxetine dosage of 12.5 mg to 50 mg (N=104) or placebo (N=109) once daily compared to immediate-release paroxetine tablets 10 mg/day to 40 mg/day (N=106). In these three studies, the Paroxetine group was statistically superior to the placebo group in improvement of depressive symptoms as measured by the following: Mean change from baseline in the Hamilton Depression Rating Scale (HDRS) total score at Week 12, Mean change from baseline in the Hamilton Depressed Mood item score at Week 12, and Mean change from baseline in the Clinical Global Impression (CGI)–Severity of Illness score.
Long-term efficacy of Paroxetine for treatment of MDD in outpatients was established based on one randomized withdrawal study with immediate-release paroxetine tablets. Below are efficacy results from immediate-release paroxetine tablets. Patients who responded to immediate-release paroxetine tablets (HDRS total score <8) during an initial 8-week open-label treatment phase were then randomized to continue immediate-release paroxetine tablets or placebo, for up to 1 year.
Patients treated with immediate-release paroxetine tablets demonstrated a statistically significant lower relapse rate during the withdrawal phase (15%) compared to those treated with placebo (39%). Effectiveness was similar in male and female patients.
14.2Clinical Studies in Panic Disorder The effectiveness of Paroxetine in the treatment of panic disorder (PD) was evaluated in three 10-week, multicenter, flexible-dose studies (Studies 4, 5, and 6) that compared Paroxetine (12.5 to 75 mg once daily) to placebo in adult outpatients 19 to 72 years of age who met panic disorder (with or without agoraphobia) criteria according to DSM-IV. The key endpoints in these trials were: 1. Proportions of patients free of full panic attacks at Week 10; 2.
Change from baseline to Week 10 in the median number of full panic attacks; and 3. Change from baseline to Week 10 in the median Clinical Global Impression Severity score. For all three studies, the mean dosage of Paroxetine for completers at Week 10 was approximately 50 mg once daily.
For Studies 4 and 5, the Paroxetine group was superior to the placebo group on 2 of these 3 endpoints. Study 6 failed to consistently demonstrate a statistically significant difference between the Paroxetine and placebo groups in the three endpoints. Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.
Long-term maintenance effects of Paroxetine in patients with PD were demonstrated in a randomized-withdrawal study with immediate-release paroxetine tablets. Below are efficacy results from immediate-release paroxetine tablets. Patients who were responders during a 10-week, double-blind trial (followed by a 3-month double-blind maintenance phase) of immediate-release paroxetine tablets were re-randomized to continue immediate-release paroxetine tablets or placebo in a 3-month, double-blind withdrawal phase.
Patients treated with immediate-release paroxetine tablets were statistically significantly less likely to relapse than patients treated with placebo.
14.3Clinica… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Two-year carcinogenicity studies were conducted in rodents given paroxetine in the diet at 1, 5, and 25 mg/kg/day in mice and 1, 5, and 20 mg/kg/day in rats. In mice, these doses were up to approximately 1.6 (mouse) and 2.5 (rat) times the MRHD of Paroxetine on an mg/m 2 basis. There was a significantly greater number of male rats in the high-dose group with reticulum cell sarcomas (1/100, 0/50, 0/50, and 4/50 for control, low-, middle-, and high-dose groups, respectively) and a significantly increased linear trend across dose groups for the occurrence of lymphoreticular tumors in male rats.
Female rats were not affected. Although there was a dose-related increase in the number of tumors in mice, there was no drug-related increase in the number of mice with tumors. The relevance of these findings to humans is unknown.
Mutagenesis Paroxetine produced no genotoxic effects in a battery of 5 in vitro and 2 in vivo assays that included the following: Bacterial mutation assay, mouse lymphoma mutation assay, unscheduled DNA synthesis assay, and tests for cytogenetic aberrations in vivo in mouse bone marrow and in vitro in human lymphocytes and in a dominant lethal test in rats. Impairment of Fertility Some clinical studies have shown that SSRIs (including paroxetine) may affect sperm quality during SSRI treatment, which may affect fertility in some men [see Use in Specific Populations ( 8.3 )].
A reduced pregnancy rate was found in reproduction studies in rats at a dose of paroxetine of 15 mg/kg/day, which is approximately twice the MRHD of Paroxetine on an mg/m 2 basis. Irreversible lesions occurred in the reproductive tract of male rats after dosing in toxicity studies for 2 to 52 weeks. These lesions consisted of vacuolation of epididymal tubular epithelium at 50 mg/kg/day and atrophic changes in the seminiferous tubules of the testes with arrested spermatogenesis at 25 mg/kg/day (approximately 6 and 3 times the MRHD of Paroxetine on an mg/m 2 basis).
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Two-year carcinogenicity studies were conducted in rodents given paroxetine in the diet at 1, 5, and 25 mg/kg/day in mice and 1, 5, and 20 mg/kg/day in rats. In mice, these doses were up to approximately 1.6 (mouse) and 2.5 (rat) times the MRHD of Paroxetine on an mg/m 2 basis. There was a significantly greater number of male rats in the high-dose group with reticulum cell sarcomas (1/100, 0/50, 0/50, and 4/50 for control, low-, middle-, and high-dose groups, respectively) and a significantly increased linear trend across dose groups for the occurrence of lymphoreticular tumors in male rats.
Female rats were not affected. Although there was a dose-related increase in the number of tumors in mice, there was no drug-related increase in the number of mice with tumors. The relevance of these findings to humans is unknown.
Mutagenesis Paroxetine produced no genotoxic effects in a battery of 5 in vitro and 2 in vivo assays that included the following: Bacterial mutation assay, mouse lymphoma mutation assay, unscheduled DNA synthesis assay, and tests for cytogenetic aberrations in vivo in mouse bone marrow and in vitro in human lymphocytes and in a dominant lethal test in rats. Impairment of Fertility Some clinical studies have shown that SSRIs (including paroxetine) may affect sperm quality during SSRI treatment, which may affect fertility in some men [see Use in Specific Populations ( 8.3 )].
A reduced pregnancy rate was found in reproduction studies in rats at a dose of paroxetine of 15 mg/kg/day, which is approximately twice the MRHD of Paroxetine on an mg/m 2 basis. Irreversible lesions occurred in the reproductive tract of male rats after dosing in toxicity studies for 2 to 52 weeks. These lesions consisted of vacuolation of epididymal tubular epithelium at 50 mg/kg/day and atrophic changes in the seminiferous tubules of the testes with arrested spermatogenesis at 25 mg/kg/day (approximately 6 and 3 times the MRHD of Paroxetine on an mg/m 2 basis).
📄 Package Label / Principal Display Panel ▾
12.5mg NDC 62175- 470 -32 Paroxetine Extended-Release Tablets, USP 12.5 mg Print Medication Guides at: www.lannett.com/med-guide/paroxetine Rx Only 30 Tablets 12.5 mg 30 count
25 mg NDC 62175- 471 -32 Paroxetine Extended-Release Tablets, USP 25 mg Print Medication Guides at: www.lannett.com/med-guide/paroxetine Rx Only 30 Tablets 25 mg 30 count
37.5mg NDC 62175- 472 -32 Paroxetine Extended-Release Tablets, USP 37.5 mg Print Medication Guides at: www.lannett.com/med-guide/paroxetine Rx Only 30 Tablets 37.5 mg 30 count